Page 40 - TD-2-2

Tumor Discovery A comprehensive review of bexarotene

X receptor agonist Bexarotene (Targretin) synergistically progression in mice with preinvasive breast disease. Cancer
enhances the growth inhibitory activity of cytotoxic drugs Prev Res (Phila), 6(12): 1273–1282.
in non-small cell lung cancer cells. Lung Cancer, 50(1): 9–18.
https://doi.org/10.1158/1940-6207.CAPR-13-0182
https://doi.org/10.1016/j.lungcan.2005.05.008
36. Ying SX, Seal S, Abbassi N, et al., 2007, Differential effects of
26. Dragnev KH, Whyman JD, Hahn CK, et al., 2018, A phase Bexarotene on intrinsic and extrinsic pathways in TRAIL-
I/II study of Bexarotene with Carboplatin and weekly induced apoptosis in two myeloid leukemia cell lines. Leuk
paclitaxel for the treatment of patients with advanced non- Lymphoma, 48(5): 1003–1014.
small cell lung cancer. J Thorac Dis, 10(9): 5531–5537.
https://doi.org/10.1080/10428190701242358
https://doi.org/10.21037/jtd.2018.09.10
37. Klopper JP, Berenz A, Hays WR, et al., 2008, In vivo and
27. Padda SK, Chhatwani L, Zhou L, et al., 2013, Phase I and microarray analysis of rexinoid-responsive anaplastic
pharmacokinetic study of Bexarotene in combination with thyroid carcinoma. Clin Cancer Res, 14(2): 589–596.
gefitinib in the third-line treatment of non-small-cell lung
cancer: Brief report. Anticancer Drugs, 24(7): 731–735. https://doi.org/10.1158/1078-0432.CCR-07-0269
https://doi.org/10.1097/CAD.0b013e32836100d7 38. Liu YY, 2006, Bexarotene increases uptake of radioiodide
in metastases of differentiated thyroid carcinoma. Eur J
28. Ai X, Mao F, Shen S, et al., 2018, Bexarotene inhibits the Endocrinol, 154(4): 525–531.
viability of non-small cell lung cancer cells via slc10a2/
PPARγ/PTEN/mTOR signaling pathway. BMC Cancer, https://doi.org/10.1530/eje.1.02123
18(1): 407. 39. Saito-Hakoda A, Uruno A, Yokoyama A, et al., 2015, Effects
https://doi.org/10.1186/s12885-018-4224-x of RXR agonists on cell proliferation/apoptosis and ACTH
secretion/POMC expression. PLoS One, 10(12): e0141960.
29. Esteva FJ, Valero V, Pusztai L, et al., 2001, Chemotherapy
of metastatic breast cancer: What to expect in 2001 and https://doi.org/10.1371/journal.pone.0141960
beyond. Oncologist, 6: 133–146. 40. Castillo V, Giacomini D, Páez-Pereda M, et al., 2006,
https://doi.org/10.1634/theoncologist.6-2-133 Retinoic acid as a novel medical therapy for Cushing’s
disease in dogs. Endocrinology, 147(9): 4438–4444.
30. Welsch CW, 1985, Host factors affecting the growth of
carcinogen-induced rat mammary carcinomas: A review https://doi.org/10.1210/en.2006-0414
and tribute to Charles Brenton Huggins. Cancer Res, 41. Atmaca H, Islek I, Senturk N, 2013, Reversible pituitary
45: 3415–3443. insufficiency due to Bexarotene therapy in a patient with
31. Gottardis MM, Jordan VC, 1987, Antitumor actions of mycosis fungoides. Pituitary, 17(5): 492–493.
keoxifene and tamoxifen in the N-nitrosomethylurea- https://doi.org/10.1007/s11102-013-0523-z
induced rat mammary carcinoma model. Cancer Res,
47: 4020–4024. 42. Yu H, Ren S, Wang J, et al., 2020, Bexarotene combined with
Lapatinib for the treatment of Cushing’s disease: Evidence
32. Yen WC, Lamph WW, 2005, The selective retinoid X based on drug repositioning and experimental confirmation.
receptor agonist Bexarotene (LGD1069, Targretin) prevents Signal Transduct Target Ther, 5(1): 175.
and overcomes multidrug resistance in advanced breast
carcinoma. Mol Cancer Ther, 4(5): 824–834. https://doi.org/10.1038/s41392-020-00284-7
https://doi.org/10.1158/1535-7163.MCT-05-0018 43. Talpur R, Vu J, Bassett R, et al., 2019, Phase I/II randomized
bilateral half-head comparison of topical Bexarotene 1% gel
33. Kong JN, He Q, Wang G, et al., 2015, Guggulsterone and for alopecia areata. J Am Acad Dermatol, 61: 592–598.e1-9.
Bexarotene induce secretion of exosome-associated breast
cancer resistance protein and reduce doxorubicin resistance https://doi.org/10.1016/j.jaad.2009.02.037
in MDA-MB-231 cells. Int J Cancer, 137(7): 1610–1620. 44. Dong H, Wang H, Wang L, 2020, Inhibition of MAPT
https://doi.org/10.1002/ijc.29542 enhances the effect of Bexarotene and attenuates the damage
after traumatic brain injury using in vivo and in vitro
34. Kong G, Kim HT, Wu K, et al., 2005, The retinoid X experiments. Folia Neuropathol, 58(3): 253–264.
receptor-selective retinoid, LGD1069, down-regulates
cyclooxygenase-2 expression in human breast cells through https://doi.org/10.5114/fn.2020.100068
transcription factor crosstalk: Implications for molecular- 45. Chang CF, Massey J, Osherov A, et al., 2020, Bexarotene
based chemoprevention. Cancer Res, 65(8): 3462–3469. enhances macrophage erythrophagocytosis and hematoma
https://doi.org/10.1158/0008-5472.CAN-03-2912 clearance in experimental intracerebral hemorrhage. Stroke,
51: 612–618.
35. Disis ML, Gad E, Herendeen DR, et al., 2013, A multiantigen
vaccine targeting neu, IGFBP-2, and IGF-IR prevents tumor https://doi.org/10.1161/STROKEAHA.119.027037

Volume 2 Issue 2 (2023) 14 https://doi.org/10.36922/td.0436